Asia Pacific Acute Coronary Syndrome Market Analysis

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Asia Pacific Acute Coronary Syndrome Market Analysis

  • Healthcare
  • Published Report
  • Mar 2022
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 64
  • No of Figures: 35

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 SERVICES LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTERS FIVE FORCES

5 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET: REGULATORY SCENARIO

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISE IN PREVALENCE OF CHRONIC DISEASES, SUCH AS CORONARY ARTERY DISEASE, ISCHEMIC HEART DISEASE, AND VASCULAR DISEASES

6.1.2 GROWING GERIATRIC POPULATION

6.1.3 WIDE RANGE OF PRODUCTS OFFERED BY MARKET PLAYERS

6.1.4 IMPROVING HEALTHCARE INFRASTRUCTURE AND REIMBURSEMENT POLICIES

6.2 RESTRAINTS

6.2.1 RISE IN COST OF THERAPEUTIC SURGERY

6.2.2 STRINGENT RULES & REGULATIONS

6.3 OPPORTUNITIES

6.3.1 SURGE IN TECHNOLOGICAL ADVANCEMENTS FOR CARDIOVASCULAR DISEASE

6.3.2 RISING HEALTHCARE EXPENDITURE

6.3.3 INCREASED REIMBURSEMENT POLICIES

6.3.4 RISING DISEASE MANAGEMENT PROGRAMS

6.4 CHALLENGES

6.4.1 LACK OF ACCESSIBILITY OF SERVICES

6.4.2 LONG PROCESS OF APPROVAL BY REGULATORY BODIES

7 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET, BY TYPE

7.1 OVERVIEW

7.2 NON-ST- ELEVATION MYOCARDIAL INFARCTION

7.3 ST-ELEVATION MYOCARDIAL INFARCTION

7.4 UNSTABLE ANGINA

8 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS

8.1 OVERVIEW

8.2 STRESS TEST

8.3 BLOOD TEST

8.4 IMAGING

8.5 OTHERS

9 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET, BY TREATMENT

9.1 OVERVIEW

9.2 MEDICATION

9.3 SURGERY

10 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET, BY END USER

10.1 OVERVIEW

10.2 HOSPITALS AND CLINICS

10.3 DIAGNOSTIC CENTERS

10.4 ACADEMIC INSTITUTES

10.5 OTHERS

11 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET, BY REGION

11.1 ASIA-PACIFIC

11.1.1 CHINA

11.1.2 JAPAN

11.1.3 INDIA

11.1.4 SOUTH KOREA

11.1.5 AUSTRALIA

11.1.6 THAILAND

11.1.7 MALAYSIA

11.1.8 SINGAPORE

11.1.9 INDONESIA

11.1.10 PHILIPPINES

11.1.11 REST OF ASIA-PACIFIC

12 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET: COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC

13 SWOT ANALYSIS

14 COMPANY PROFILE

14.1 NOVARTIS AG

14.1.1 COMPANY SNAPSHOT

14.1.2 REVENUE ANALYSIS

14.1.3 COMPANY SHARE ANALYSIS

14.1.4 PRODUCT PORTFOLIO

14.1.5 RECENT DEVELOPMENTS

14.1.5.1 PRODUCT EXPANSION

14.1.5.2 COLLABRATION

14.2 ASTRA ZENECA

14.2.1 COMPANY SNAPSHOT

14.2.2 REVENUE ANALYSIS

14.2.3 COMPANY SHARE ANALYSIS

14.2.4 PRODUCT PORTFOLIO

14.2.5 RECENT DEVELOPMENT

14.2.5.1 ACQUISITION

14.3 AMGEN INC.

14.3.1 COMPANY SNAPSHOT

14.3.2 REVENUE ANALYSIS

14.3.3 COMPANY SHARE ANALYSIS

14.3.4 PRODUCT PORTFOLIO

14.3.5 RECENT DEVELOPMENTS

14.4 SANOFI

14.4.1 COMPANY SNAPSHOT

14.4.2 REVENUE ANALYSIS

14.4.3 COMPANY SHARE ANALYSIS

14.4.4 PRODUCT PORTFOLIO

14.4.5 RECENT DEVELOPMENT

14.4.5.1 ACQUISITION

14.5 BAXTER

14.5.1 COMPANY SNAPSHOT

14.5.2 REVENUE ANALYSIS

14.5.3 COMPANY SHARE ANALYSIS

14.5.4 PRODUCT PORTFOLIO

14.5.5 RECENT DEVELOPMENTS

14.6 DR. REDDY’S LABORATORIES LTD.

14.6.1 COMPANY SNAPSHOT

14.6.2 REVENUE ANALYSIS

14.6.3 PRODUCT PORTFOLIO

14.6.4 RECENT DEVELOPMENTS

14.6.4.1 ACQUISTION

14.7 PFIZER INC.

14.7.1 COMPANY SNAPSHOT

14.7.2 REVENUE ANALYSIS

14.7.3 PRODUCT PORTFOLIO

14.7.4 RECENT DEVELOPMENT

14.8 MERCK & CO., INC.

14.8.1 COMPANY SNAPSHOT

14.8.2 REVENUE ANALYSIS

14.8.3 PRODUCT PORTFOLIO

14.8.4 RECENT DEVELOPMENTS

14.8.4.1 EVENT

14.8.4.2 ACQUISTION

14.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

14.9.1 COMPANY SNAPSHOT

14.9.2 PRODUCT PORTFOLIO

14.9.3 RECENT DEVELOPMENT

14.9.3.1 PRODUCT APPROVAL

14.1 CSL

14.10.1 COMPANY SNAPSHOT

14.10.2 REVENUE ANALYSIS

14.10.3 PRODUCT PORTFOLIO

14.10.4 RECENT DEVELOPMENT

14.10.4.1 ACQUISITION

14.11 DAIICHI SANKYO COMPANY,LIMITED

14.11.1 COMPANY SNAPSHOT

14.11.2 REVENUE ANALYSIS

14.11.3 PRODUCT PORTFOLIO

14.11.4 RECENT DEVELOPMENT

14.11.4.1 PARTNERSHIP

14.12 JOHNSON & JOHNSON SERVICES, INC.

14.12.1 COMPANY SNAPSHOT

14.12.2 REVENUE ANALYSIS

14.12.3 PRODUCT PORTFOLIO

14.12.4 RECENT DEVELOPMENT

14.12.4.1 ACQUISITION

14.13 TEVA PHARMACEUTICAL INDUSTRIES LTD.

14.13.1 COMPANY SNAPSHOT

14.13.2 REVENUE ANALYSIS

14.13.3 PRODUCT PORTFOLIO

14.13.4 RECENT DEVELOPMENT

14.13.4.1 ACQUISITION

14.14 REGENERON PHARMACEUTICALS INC.

14.14.1 COMPANY SNAPSHOT

14.14.2 REVENUE ANALYSIS

14.14.3 PRODUCT PORTFOLIO

14.14.4 RECENT DEVELOPMENT

15 QUESTIONNAIRE

16 RELATED REPORTS

List of Table

TABLE 1 LIST OF RECENT PROGRESS OF 3D BIO PRINTING FOR CARDIAC TISSUE ENGINEERING-

TABLE 2 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 3 ASIA PACIFIC NON-ST-ELEVATION MYOCARDIAL INFARCTION IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 ASIA PACIFIC ST—ELEVATION MYOCARDIAL INFARCTION IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 ASIA PACIFIC UNSTABLE ANGINA IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)

TABLE 7 ASIA PACIFIC STRESS TEST IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 ASIA PACIFIC BLOOD TEST IN ACUTE SYNDROME CORONARY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 9 ASIA PACIFIC IMAGING IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 ASIA PACIFIC OTHERS IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 12 ASIA PACIFIC MEDICATION IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 ASIA PACIFIC SURGERY IN ACUTE CORONARY SYNDROME MARKET, BY REGION 2020-2029 (USD MILLION)

TABLE 14 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 15 ASIA PACIFIC HOSPITALS AND CLINICS IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 ASIA PACIFIC DIAGNOSTIC CENTERS IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 ASIA PACIFIC ACADEMIC INSTITUTES IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 ASIA PACIFIC OTHERS IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 ASIA-PACIFIC ACUTE CORONARY SYNDROME MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 20 ASIA-PACIFIC ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 21 ASIA-PACIFIC ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)

TABLE 22 ASIA-PACIFIC ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 23 ASIA-PACIFIC ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 24 CHINA ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 25 CHINA ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)

TABLE 26 CHINA ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 27 CHINA ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 28 JAPAN ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 29 JAPAN ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)

TABLE 30 JAPAN ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 31 JAPAN ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 32 INDIA ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 33 INDIA ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)

TABLE 34 INDIA ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 35 INDIA ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 36 SOUTH KOREA ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 37 SOUTH KOREA ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)

TABLE 38 SOUTH KOREA ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 39 SOUTH KOREA ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 40 AUSTRALIA ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 41 AUSTRALIA ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)

TABLE 42 AUSTRALIA ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 43 AUSTRALIA ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 44 THAILAND ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 45 THAILAND ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)

TABLE 46 THAILAND ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 47 THAILAND ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 48 MALAYSIA ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 49 MALAYSIA ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)

TABLE 50 MALAYSIA ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 51 MALAYSIA ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 52 SINGAPORE ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 53 SINGAPORE ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)

TABLE 54 SINGAPORE ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 55 SINGAPORE ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 56 INDONESIA ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 57 INDONESIA ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)

TABLE 58 INDONESIA ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 59 INDONESIA ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 60 PHILIPPINES ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 61 PHILIPPINES ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)

TABLE 62 PHILIPPINES ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 63 PHILIPPINES ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 64 REST OF ASIA-PACIFIC ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)

List of Figure

FIGURE 1 ASIA PACIFIC ACUTE CORONNARY SYNDROME MARKET: SEGMENTATION

FIGURE 2 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET: DATA TRIANGULATION

FIGURE 3 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET: DROC ANALYSIS

FIGURE 4 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET: DBMR MARKET POSITION GRID

FIGURE 8 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET: DBMR VENDOR SHARE ANALYSIS

FIGURE 9 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET: SEGMENTATION

FIGURE 10 NORTH AMERICA IS EXPECTED TO DOMINATE THE ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 11 RISING PREVALENCE OF CORONARY ARTERY DISEASE, ISCHEMIC HEART AND VASCULAR DISEASE AS WELL AS GROWING GERIATRIC POPULATION IS DRIVING THE ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET IN 2022 & 2029

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET

FIGURE 14 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET: BY TYPE, 2021

FIGURE 15 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET: BY TYPE, 2022-2029 (USD MILLION)

FIGURE 16 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 17 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET: BY TYPE, LIFELINE CURVE

FIGURE 18 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET: BY DIAGNOSIS, 2021

FIGURE 19 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET: BY DIAGNOSIS, 2022-2029 (USD MILLION)

FIGURE 20 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET: BY DIAGNOSIS, CAGR (2022-2029)

FIGURE 21 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET: BY DIAGNOSIS, LIFELINE CURVE

FIGURE 22 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET: BY TREATMENT, 2021

FIGURE 23 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET: BY TREATMENT, 2022-2029 (USD MILLION)

FIGURE 24 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET: BY TREATMENT, CAGR (2022-2029)

FIGURE 25 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 26 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET: BY END USER, 2021

FIGURE 27 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 28 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET: BY END USER, CAGR (2022-2029)

FIGURE 29 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET: BY END USER, LIFELINE CURVE

FIGURE 30 ASIA-PACIFIC ACUTE CORONARY SYNDROME MARKET: SNAPSHOT (2021)

FIGURE 31 ASIA-PACIFIC ACUTE CORONARY SYNDROME MARKET: BY COUNTRY (2021)

FIGURE 32 ASIA-PACIFIC ACUTE CORONARY SYNDROME MARKET: BY COUNTRY (2022 & 2029)

FIGURE 33 ASIA-PACIFIC ACUTE CORONARY SYNDROME MARKET: BY COUNTRY (2021 & 2029)

FIGURE 34 ASIA-PACIFIC ACUTE CORONARY SYNDROME MARKET: BY TYPE (2022-2029)

FIGURE 35 ASIA PACIFIC ACUTE CORONARY SYNDROME MARKET: COMPANY SHARE 2021 (%)

Frequently Asked Questions

The Asia-Pacific Acute Coronary Syndrome Market will be projected to grow at a CAGR of 6.1% during the forecast by 2029.
The Asia-Pacific Acute Coronary Syndrome Market will be projected at USD 3,304.22 million during the forecast by 2029.
The major players operating in the Asia-Pacific Acute Coronary Syndrome Market AstraZeneca, Daiichi Sankyo company, Johnson & Johnson Service Inc., Amgen Inc., Pfizer Inc., Regeneron Pharmaceuticals Inc, Sanofi, CSL Behring, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Baxter, Dr. Reddy’s Laboratories, Merck & Co., Inc. and Novartis AG and among others.
Rise in cost of the therapeutic surgery and lack of accessibility of disease management services and support in low economic countries are poised to restrict the Asia-Pacific Acute Coronary Syndrome Market growth.